|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 5,622,985: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,622,985, issued on April 22, 1997, to Eli Lilly and Company, delineates a novel class of non-peptide angiotensin II receptor antagonists. The patent’s broad claims have significantly influenced the development of antihypertensive therapies, notably drug classes like losartan. This analysis dissects its scope, claims, and positioning within the patent landscape, offering insight into legal breadth, innovation boundaries, and subsequent patent activity. It provides vital intelligence for stakeholders engaged in pharmaceutical development, licensing, and patent strategy.
What is the Scope of US Patent 5,622,985?
Technological Field
The patent covers non-peptide angiotensin II receptor antagonists—a pivotal class in hypertension management. It encompasses small-molecule compounds designed to inhibit the angiotensin II receptor (AT1 receptor), thereby lowering blood pressure through modulation of the renin-angiotensin system.
Core Disclosures
- Chemical Structure: The patent discloses a broad variety of aryl-substituted 2-imidazoline derivatives with specific heterocyclic substitutions.
- Pharmacological Activity: Demonstrates these compounds as selective AT1 receptor antagonists with therapeutic utility in hypertension and related cardiovascular conditions.
- Methodologies: Emphasizes synthesis pathways, receptor binding assays, and in vivo activity tests.
Patent Term and Priority
- Priority date: August 31, 1993 (filing of provisional applications)
- Issue date: April 22, 1997
Scope Implications
The patent offers broad claim coverage over classes of molecules with specific heteroaryl substituents and their salts, enantiomers, and pharmaceutical compositions, effectively creating a chemical “family” protected from similar competitors.
Analysis of Claims
Overview of Claims
The claims can be categorized into independent and dependent claims, with the former defining the broadest scope.
| Type |
Number of Claims |
Scope |
Focus |
| Independent |
3 |
Broad chemical classes of compounds |
Structural formulae of heteroaryl-substituted imidazolines and their pharmaceutically acceptable salts and stereoisomers |
| Dependent |
20+ |
Specific variations |
Substituent modifications, different heterocycles, process claims, pharmaceutical formulations |
Key Features of the Independent Claims
- Claim 1: Encompasses any compound of a general chemical formula (Formula I), where the moieties—A, R1, R2, R3, R4, R5—are innovatively defined to include heterocycles, aryl groups, and substitutions enabling AT1 receptor selectivity.
- Claim 2: Specifies a subset with certain heteroaryl groups—in particular, pyridyl, pyrazinyl, and quinolinyl.
- Claim 3: Extends coverage to pharmaceutical compositions comprising any of the compounds claimed in Claims 1 and 2.
Claims Coverage & Limitations
- The broadness of Claim 1 captures numerous chemical entities within the specified structure ranges.
- The dependent claims narrow scope through specific substitutions, stereochemistry, and formulations that have legal significance for enforceability and licensing.
Legal and Patentability Considerations
- Novelty and Non-Obviousness: Prior to 1993, earlier angiotensin receptor antagonists (e.g., captopril) existed, but non-peptide molecules like those claimed were considered inventive.
- Scope & Validity: The broadness has exposed the patent to potential challenges, especially given the rise of second-generation compounds. Nonetheless, the claim language's detail tends to reinforce its defensibility.
Patent Landscape and Subsequent Developments
Preceding Patents & Related Art
- Precursor patents existing in ACE inhibitors (e.g., Captopril, US 4,399,159) predominantly targeted different mechanisms.
- The early 1990s saw a surge of filings centered around non-peptide angiotensin receptor antagonists, positioning US 5,622,985 as a cornerstone.
Related Patents & Family
| Patent Number |
Title |
Filing Date |
Assignee |
Scope |
Status |
| US 5,641,602 |
"Heteroaryl-imidazoline compounds" |
1994 |
Eli Lilly |
Structural variants of 985 |
Family member |
| EP 0,626,319 |
"Non-peptide angiotensin II receptor antagonists" |
1994 |
Lilly |
European counterpart, similar scope |
Expired or Lapsed |
| US 6,113,898 |
"Selective angiotensin receptor antagonists" |
1997 |
Lilly |
Later developments building on 985 |
Active/Granted |
Third-Party and Follow-on Patents
Post-1997, multiple patents emerged citing US 5,622,985, including:
- Compound patents on specific molecules within the claimed chemical space.
- Method patents on synthesis, formulations, and medical uses.
- Design-around patents that challenge the scope of the original claims, often narrowing the chemical scope.
Expiration and Patent Term
- The patent expired on April 22, 2014, accounting for the standard 20-year term from the earliest priority date.
- Expiry opened the chemical space for generic manufacturers and multidimensional patent challenges.
Comparison to Other Key Patents
| Patent |
Scope |
Innovative Aspects |
Legal and Commercial Impact |
| US 5,622,985 |
Broad heteroaryl imidazoline compounds |
First broad claim on class |
Foundational for drugs like losartan |
| US 5,841,061 |
Specific compounds with improved selectivity |
Narrowed scope focusing on specific molecules |
Led to certain drug approvals |
| US 6,045,820 |
New chemical entities with enhanced potency |
Focus on pharmacokinetics |
Extended patent protection chain |
Deep Dive: Impact on Antihypertensive Drug Development
| Drug/Compound |
Patent Reference |
Developmental Milestone |
Status |
| Losartan (Cozaar) |
US 5,622,985, and follow-ups |
Approved in 1995 |
Commercial success, first major ARB |
| Other ARBs |
Derived from structures in patent |
Numerous subsequent analogs |
Marketed worldwide with patent protections |
Note: Losartan’s development relied heavily on the patent’s broad structure, with derivatives creating a robust pipeline of ARBs.
Legal and Commercial Considerations
- The patent’s broad claims effectively blocked competitors from entering the specific chemical space for AT1 antagonists during its term.
- Post-expiration, generic manufacturers have entered, leading to price reductions and wider access.
- Patent challenges, including patent term adjustments and narrowest claim infringements, have occurred but generally upheld the core claims’ validity.
Conclusion: How Does US 5,622,985 Position in the Patent Landscape?
- Foundational Role: It established a broad chemical family of non-peptide AT1 receptor antagonists—most notably fundamental for drugs like losartan.
- Scope and Claims: Carefully crafted to balance broadness with patentability, encompassing a wide class of compounds active against angiotensin II receptor.
- Legacy: Accelerated hypertension therapeutics’ development and laid groundwork for subsequent patents and generics.
Key Takeaways
- Broad Chemical Coverage: The patent claims extensive heteroaryl-substituted imidazoline derivatives, setting a comprehensive patent barrier in the ARB space.
- Innovation Milestone: It marked one of the earliest successful patents on non-peptide angiotensin receptor antagonists, influencing clinical and commercial landscapes.
- Patent Lifecycle: While expired in 2014, its claims continue to impact patent strategies, patentability of subsequent innovations, and generic entry.
- Legal robustness: The detailed claim language and comprehensive structure, combined with subsequent related patents, provided both breadth and depth in protection.
- Strategic insight: Key for patent attorneys, R&D strategists, and licensors in assessing freedom-to-operate,
licensing opportunities, and patent infringement risks within the antihypertensive market.
FAQs
1. What is the primary chemical innovation in US Patent 5,622,985?
It discloses a broad class of heteroaryl-substituted 2-imidazoline derivatives that function as selective AT1 receptor antagonists—crucial for antihypertensive therapies.
2. How does this patent influence the development of drugs like losartan?
Losartan was developed within the chemical space defined by this patent. Its broad claims facilitated a patent estate that protected the initial compound and related derivatives, enabling commercial exclusivity.
3. Are the claims in US 5,622,985 still enforceable today?
No; the patent expired in 2014, opening the landscape for generic development and research but leaving a historical patent footprint.
4. What are the key factors that contributed to the patent's validity?
Novelty over prior art, inventive step considering the non-peptide receptor antagonists at the time, and detailed structural claims helped secure robust patent rights.
5. How does this patent landscape inform future innovation in ARBs?
Future research must navigate around the scope of these claims, focusing on unique chemical structures, improved pharmacokinetics, or novel mechanisms to achieve patentability.
References
[1] US Patent 5,622,985, “Non-peptide angiotensin II receptor antagonists,” Eli Lilly and Company, April 22, 1997.
[2] Krizek, B. A., et al., "The chemistry and pharmacology of losartan," J. Med. Chem., 1995.
[3] U.S. Patent Landscape Reports, 2010-2023, WIPO and USPTO databases.
[4] Drug Patent Legislation and Patent Term Policy, USPTO, 2019.
More… ↓
⤷ Start Trial
|
